|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | VaxGen |
|---|---|
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00006327 |
Purpose
The purpose of this study is to determine if the vaccine, AIDSVAX B/E, will protect intravenous drug users from becoming infected with HIV.
| Condition | Intervention | Phase |
|---|---|---|
|
HIV Infections HIV Seronegativity |
Biological: MN rgp120/HIV-1 and A244 rgp120/HIV-1 |
Phase III |
| Study Type: | Interventional |
| Study Design: | Prevention, Double-Blind, Efficacy Study |
| Official Title: | A Phase III Trial to Determine the Efficacy of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand |
| Estimated Enrollment: | 2500 |
| Study Start Date: | March 1999 |
| Estimated Study Completion Date: | August 2000 |
Volunteers are immunized and followed for a minimum of 2 years. Any volunteer that becomes infected with HIV-1 is followed every 4 months post infection for up to 36 months. Behavior effects associated with study participation are assessed.
Eligibility| Ages Eligible for Study: | 20 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria
Volunteers may be eligible for this study if they:
Exclusion Criteria
Volunteers will not be eligible for this study if they:
Contacts and Locations
More Information
| Study ID Numbers: | VAX 003 |
| Study First Received: | October 2, 2000 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00006327 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Recombinant Proteins HIV-1 AIDS Serodiagnosis Substance Abuse, Intravenous |
Enzyme-Linked Immunosorbent Assay Blotting, Western HIV Envelope Protein gp120 AIDSVAX |
|
Virus Diseases Sexually Transmitted Diseases, Viral RNA Virus Infections Slow Virus Diseases Immune System Diseases HIV Infections |
Sexually Transmitted Diseases Acquired Immunodeficiency Syndrome Lentivirus Infections Infection Retroviridae Infections Immunologic Deficiency Syndromes |